aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma's Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint of reducing mean daily oral corticosteroid (OCS) dose at week 48 (p=0.3313). However, the study demonstrated nominal statistical significance in key secondary measures, including clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score (p=0.0479) and a greater proportion of patients achieving complete steroid withdrawal with KSQ-Lung improvement (29.5% vs. 14.4% placebo, p=0.0199). Despite the primary endpoint miss, aTyr Pharma plans to engage with the FDA, citing these clinically relevant efficacy findings and the drug's well-tolerated safety profile, indicating a potential, albeit uncertain, regulatory path forward for efzofitimod.

Analysis

aTyr Pharma's (ATYR) Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis failed to achieve its primary endpoint, which was a statistically significant reduction in mean daily oral corticosteroid (OCS) dose versus placebo (p=0.3313). This is a significant setback for the program. The company is highlighting several secondary endpoints that showed nominal statistical significance, including an improvement in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score (p=0.0479) and a greater proportion of patients achieving complete steroid withdrawal with an improved KSQ-Lung score (29.5% vs 14.4% for placebo, p=0.0199). However, due to the study's hierarchical statistical design, these subsequent findings are not statistically valid following the primary endpoint failure. While the drug was well-tolerated, its regulatory path is now highly uncertain. aTyr's management plans to engage with the U.S. FDA to discuss the totality of the data, shifting the immediate focus from clinical efficacy to regulatory risk and the FDA's potential flexibility.

Key Decisions for Investors

• Investors should anticipate significant negative pressure on ATYR's valuation due to the primary endpoint failure, as the commercial and regulatory pathway for efzofitimod is now materially more challenging and uncertain.
• The pivotal near-term catalyst is the outcome of the company's planned discussion with the FDA; the viability of this asset now depends on regulatory discretion rather than on clear clinical trial success.
• Given the high degree of regulatory uncertainty, consider reducing exposure or hedging positions, as a 'totality of data' argument to regulators is a low-probability path to approval without a new, successful trial.